Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)

HIV Clinical Trials

Volumn 10, Issue 6, 2009, Pages 343-355

  Clifford, David B ^a   Evans, Scott ^b   Yang, Yijun ^b   Acosta, Edward P ^c   Ribaudo, Heather ^b   Gulick, Roy M ^d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Anxiety; Depression; Efavirenz; HIV therapy; Neuropsychologic effects; Sleep

Indexed keywords

ABACAVIR; EFAVIRENZ; LAMIVUDINE; PLACEBO; ZIDOVUDINE;

ADULT; ARTICLE; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGY; NIGHTMARE; PATIENT ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STRUCTURED QUESTIONNAIRE; TREATMENT RESPONSE;

ADULT; AGED; ANXIETY; BENZOXAZINES; BRAIN; DEPRESSION; DOUBLE-BLIND METHOD; DREAMS; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; QUESTIONNAIRES; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS;

EID: 76749119501     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1006-343     Document Type: Article

References (18)

1. Staszewski S, Morales-Ramirez J, Tashima K, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New Engl J Med. 1999;341:1865-1873.
2. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society -USA Panel. JAMA. 2008;300(5):555-570.
3. Bristol-Myers Squibb. Sustiva® (efavirenz) package insert. PDR net® . 2008.
4. Clifford DB, Evans S, Yang Y, et al. Impact on efavirenz on neuropsychological performance and symptoms in HIVinfected individuals. Ann Intern Med. 2005;143: 714-721.
5. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850-1861.
6. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three-vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection. A randomized control trial. JAMA. 2006;296:769-781.
7. Wechsler D. Wechsler Adult Intelligence Scale (WAIS-III) -Administration and scoring manual. 3rd ed. San Antonio, TX: Psychological Corp.; 1997.
8. Buysse DJ, Reynold CF, Monk TH, Kupfer DF. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Research. 1989;28:193-213.
9. Spielberger CD. State-Trait Anxiety Inventory for Adults (Form Y). Redwood City, CA: Mind Garden; 1983.
10. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measure. 1977;1:385-401.
11. Turner ML, Reed-Walker K, King JR, Acosta EP. Simultaneous quantitation of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma using a single high-performance liquid chromatography methodology. J Chromatog B. 2003;784:331-341.
12. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 1999;13: 1249-1253.
13. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J NeuroVirol. 2002;8:136-142.
14. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65-70.
15. Tashima K, Caliendo AM, Ahmad M, et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis. 1999;180:862-864.
16. Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an adult AIDS Clinical Trials Group study. Clin Infect Dis. 2005;42:401-407.
17. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-75. (Pubitemid 32055781)
18. Rihs TA, Begley K, Smith DE, et al. Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med. 2006;7:544-548.